Table 3 Univariate and multivariable regression analyses to identify predictors for bleeding complications in edoxaban users.
Predictors | Unadjusted OR | Model I | Model II | Model III | Model IV | Model V & VI | |
|---|---|---|---|---|---|---|---|
(95% CIs) | Adjusted OR | Adjusted OR | Adjusted OR | Adjusted OR | Adjusted OR | ||
(95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | |||
Age | ≥ 65 years | 1.71 (0.47–6.27) | |||||
Female | 0.49 (0.17–1.45) | ||||||
Prescription dose | Overdose | 8.69 (1.14–65.96)* | 11.36 (1.23–114.36)* | 11.01 (1.08–111.97)* | 10.86 (1.07–110.35)* | 10.82 (1.07–109.91)* | 13.60 (1.59–116.64)* |
rs4149057 (T > C) | CT, CC | 3.13(1.06–9.24)* | 3.92 (1.16–13.29)* | 3.82 (1.13–12.94)* | |||
rs999278 (C > A) | AC, AA | 3.04 (1.03–8.98)* | 3.78 (1.11–12.80)* | ||||
rs2306283 (A > G) | GG | 0.35 (0.12–1.03) | 0.27 (0.08–0.90)* | ||||
rs4149056 (T > C) | TC, CC | 4.26 (1.55–11.69)** | 5.48 (1.75–17.23)** | 5.71(1.80–18.13)** | |||
rs2417957 (C > T) | CT, TT | 0.36 (0.12–1.07) | |||||
SLCO1B1*15 carrier | Yes | 4.32 (1.57–11.87)** | 5.78 (1.82–18.36)** | 5.75 (1.81–18.24)** | |||
SLCO1B1*1A carrier | Yes | 3.006 (1.017–8.891)* | 3.00 (0.96–9.40) | ||||
ABCB1 rs3842 (T > C) | CC | 4.89 (1.57–15.18)** | 5.89 (1.61–21.56)** | 5.33 (1.45–19.55)* | 5.32(1.45–19.50)* | 5.28 (1.44–19.35)* | 5.44 (1.66–17.86)** |
